Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7285781 | 0.89 | PTGDR2 (0.69) | KDM4ERAB9APTGDR2LMNAALDH1A1 | |
| SCHEMBL29707984 | 0.88 | ALDH1A1 (0.63) | KDM4ERAB9APTGDR2LMNAERN1 | |
| SCHEMBL7840891 | 0.88 | ALDH1A1 (0.63) | KDM4ERAB9APTGDR2LMNAERN1 | |
| SCHEMBL5883150 | 0.87 | PTGDR2 (0.62) | KDM4ERAB9APTGDR2ERN1ALDH1A1 | |
| SCHEMBL8121860 | 0.87 | KDM4E (0.67) | KDM4ERAB9APTGDR2LMNAERN1 | |
| SCHEMBL15330191 | 0.87 | KDM4E (0.67) | KDM4ERAB9APTGDR2LMNAERN1 | |
| SCHEMBL2554953 | 0.84 | KDM4E (0.71) | KDM4ERAB9APTGDR2ERN1ALDH1A1 | |
| SCHEMBL3643556 | 0.83 | KDM4E (0.62) | KDM4ERAB9APTGDR2LMNAERN1 | |
| SCHEMBL7165687 | 0.83 | PPARA (0.55) | KDM4ERAB9APTGDR2ERN1ALDH1A1 | |
| SCHEMBL15332229 | 0.82 | KDM4E (0.58) | KDM4ERAB9APTGDR2ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-7071212-B2 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1149069-B1 | PHENYLGLYCINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2004-02-19 | — | — | US | disclosed |
| US-6683215-B2 | TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION AND ARTERIOSCLEROSIS, WHICH ARE ASSOCIATED WITH COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA AND TISSUE FACTOR; ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2003-05-01 | — | — | US | disclosed |
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | KDM4E 1998/4885RAB9A 1477/4885PTGDR2 1654/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | KDM4E 1998/4885RAB9A 1477/4885PTGDR2 1654/4885 |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | KDM4E 1998/4885RAB9A 1477/4885PTGDR2 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.